IL234615B - Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof - Google Patents
Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereofInfo
- Publication number
- IL234615B IL234615B IL234615A IL23461514A IL234615B IL 234615 B IL234615 B IL 234615B IL 234615 A IL234615 A IL 234615A IL 23461514 A IL23461514 A IL 23461514A IL 234615 B IL234615 B IL 234615B
- Authority
- IL
- Israel
- Prior art keywords
- hydroxymethyl
- tris
- small
- pharmaceutical compositions
- glp1r agonist
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614265P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/033091 WO2013142569A1 (en) | 2012-03-22 | 2013-03-20 | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL234615B true IL234615B (en) | 2018-02-28 |
Family
ID=49223316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL234615A IL234615B (en) | 2012-03-22 | 2014-09-11 | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9198901B2 (OSRAM) |
| EP (1) | EP2854526B1 (OSRAM) |
| JP (1) | JP2015510947A (OSRAM) |
| KR (1) | KR102158992B1 (OSRAM) |
| CN (1) | CN104202977A (OSRAM) |
| AU (1) | AU2013235167B2 (OSRAM) |
| CA (1) | CA2868033A1 (OSRAM) |
| EA (1) | EA201491749A1 (OSRAM) |
| ES (1) | ES2674951T3 (OSRAM) |
| HK (1) | HK1199371A1 (OSRAM) |
| IL (1) | IL234615B (OSRAM) |
| IN (1) | IN2014DN07867A (OSRAM) |
| MX (1) | MX352804B (OSRAM) |
| NZ (1) | NZ629203A (OSRAM) |
| SG (1) | SG11201405353VA (OSRAM) |
| WO (1) | WO2013142569A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260036616A (ko) * | 2018-05-08 | 2026-03-17 | 브이티브이 테라퓨틱스 엘엘씨 | Glp1r 작용제의 치료적 용도 |
| EP4141008A4 (en) | 2020-04-01 | 2024-04-17 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR |
| JP2023528565A (ja) | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69733752T2 (de) * | 1996-05-20 | 2006-06-01 | G.D. Searle Llc, Chicago | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz |
| AR024076A1 (es) * | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Sales de cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil) ciclohexan-1-carboxilato] |
| CA2436738A1 (en) * | 2001-02-05 | 2002-08-15 | Dr. Reddy's Laboratories Ltd. | Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| CA2463615C (en) * | 2001-10-30 | 2011-07-26 | Applied Research Systems Ars Holding N.V. | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) |
| ZA200509355B (en) * | 2003-04-18 | 2007-03-28 | Incyte San Diego Inc | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| KR101616737B1 (ko) | 2008-03-07 | 2016-05-02 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 옥사디아조안트라센 화합물 |
| JP5627453B2 (ja) * | 2008-03-31 | 2014-11-19 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター−１阻害剤 |
| AU2009255156B2 (en) * | 2008-06-05 | 2013-03-14 | Asahi Kasei Pharma Corporation | Sulfonamide compound and application thereof |
| RS53777B1 (sr) * | 2008-12-08 | 2015-06-30 | Glaxosmithkline Llc | Anhidrid 8-hlor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiola za lečenje bolesti |
| WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
-
2013
- 2013-03-20 JP JP2015501876A patent/JP2015510947A/ja not_active Ceased
- 2013-03-20 CN CN201380015508.2A patent/CN104202977A/zh active Pending
- 2013-03-20 MX MX2014010366A patent/MX352804B/es active IP Right Grant
- 2013-03-20 IN IN7867DEN2014 patent/IN2014DN07867A/en unknown
- 2013-03-20 NZ NZ629203A patent/NZ629203A/en not_active IP Right Cessation
- 2013-03-20 AU AU2013235167A patent/AU2013235167B2/en active Active
- 2013-03-20 ES ES13765015.6T patent/ES2674951T3/es active Active
- 2013-03-20 KR KR1020147026362A patent/KR102158992B1/ko active Active
- 2013-03-20 CA CA2868033A patent/CA2868033A1/en not_active Abandoned
- 2013-03-20 HK HK14112910.6A patent/HK1199371A1/xx unknown
- 2013-03-20 SG SG11201405353VA patent/SG11201405353VA/en unknown
- 2013-03-20 EP EP13765015.6A patent/EP2854526B1/en active Active
- 2013-03-20 WO PCT/US2013/033091 patent/WO2013142569A1/en not_active Ceased
- 2013-03-20 EA EA201491749A patent/EA201491749A1/ru unknown
-
2014
- 2014-09-11 IL IL234615A patent/IL234615B/en not_active IP Right Cessation
- 2014-09-18 US US14/489,890 patent/US9198901B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013142569A1 (en) | 2013-09-26 |
| EA201491749A1 (ru) | 2015-01-30 |
| AU2013235167B2 (en) | 2017-03-30 |
| ES2674951T8 (es) | 2018-08-23 |
| AU2013235167A1 (en) | 2014-09-18 |
| HK1199371A1 (en) | 2015-07-03 |
| KR102158992B1 (ko) | 2020-09-23 |
| IN2014DN07867A (OSRAM) | 2015-04-24 |
| US20150005339A1 (en) | 2015-01-01 |
| KR20140138758A (ko) | 2014-12-04 |
| MX352804B (es) | 2017-12-08 |
| US9198901B2 (en) | 2015-12-01 |
| CA2868033A1 (en) | 2013-09-26 |
| MX2014010366A (es) | 2015-05-15 |
| EP2854526B1 (en) | 2018-04-25 |
| SG11201405353VA (en) | 2014-09-26 |
| ES2674951T3 (es) | 2018-07-05 |
| EP2854526A4 (en) | 2016-02-24 |
| JP2015510947A (ja) | 2015-04-13 |
| EP2854526A1 (en) | 2015-04-08 |
| CN104202977A (zh) | 2014-12-10 |
| NZ629203A (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239457A0 (en) | Novel heterocyclic compounds as bromodomain inhibitors | |
| GEAP202413811A (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| PL3156056T3 (pl) | Kompozycje farmaceutyczne zawierające estry sorbitanu | |
| ZA201306221B (en) | Compounds and compositions as trk inhibitors | |
| ZA201305826B (en) | Substituted amminobutyric derivatives as neprilysin inhibitors | |
| ME03395B (me) | Jedinjenja i sastavi као inhibiтori с - кit kinaze | |
| LT3181567T (lt) | Pirazolpirimidino junginiai kaip kinazės slopikliai | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| EP2685986A4 (en) | Glucosylceramide SYNTHASE INHIBITORS | |
| DK3284467T3 (da) | Nikotinholdige farmaceutiske sammensætninger | |
| ZA201309154B (en) | Compositions for inhibition of insect sensing | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| IL228108A0 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| IL229488A0 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| HUE040370T2 (hu) | Gyógyszerkészítmények | |
| HUE049942T2 (hu) | Inozitolt tartalmazó gyógyszerészeti formuláció | |
| EP2688575A4 (en) | LITHIUM COMPOUNDS | |
| SG11201405353VA (en) | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof | |
| IL235919A (en) | Fbxo3 inhibitors comprising optionally-substituted n-heterocyclic substituted benzathine analogs | |
| CO6791568A2 (es) | Composiciones inmunógenas de bordetella bronchiseptica | |
| ZA201503552B (en) | Pharmaceutical compositions of cetp inhibitors | |
| PL2854792T3 (pl) | Kompozycja do zapobiegania bólom głowy | |
| EP2791669A4 (en) | EXPLOSIVE COMPOSITION | |
| EP2914249A4 (en) | TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS | |
| IL229487A0 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |